score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.4085	213.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Putatively Actionable	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	9.0	0.4444	0.5392	BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat128	MEL-IPI_Pat128-Tumor-SM-5X2R6	MEL-IPI_Pat128-Normal-SM-5VWHQ
Putatively Actionable	Preclinical	Clinical evidence		Copy Number	PTEN	Deletion				0.0	0.0		Putatively Actionable	AZD8186	PI3K/AKT/mTOR inhibition	Targeted therapy	PTEN loss of function may confer sensitivity to selective PI3K inhibition	Barlaam B, Cosulich S, Degorce S, et al. Discovery of (R)-8-(1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): a potent and selective inhibitor of PI3K-beta and PI3K-gamma for the treatment of PTEN-deficient cancers. J Med Chem. 2015;58(2):943-62.	https://doi.org/10.1021/jm501629p	Putatively Actionable	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	PTEN loss may predict resistance to immune checkpoint blockade	George S, Miao D, Demetri GD, et al. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma. Immunity. 2017;46(2):197-204.	https://doi.org/10.1016/j.immuni.2017.02.001						0				PTEN Deletion	1.0	MEL-IPI_Pat128	MEL-IPI_Pat128-Tumor-SM-5X2R6	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		MEL-IPI_Pat128	MEL-IPI_Pat128-Tumor-SM-5X2R6	
Investigate Actionability	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.L505H	0.1788	179.0	0.0	0.0		Investigate Actionability	Dabrafenib + Trametinib	B-RAF inhibition + MEK inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf. Revised April 2020. Accessed November 12, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202806s015lbl.pdf	Investigate Actionability	Panitumumab	EGFR inhibition	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0	15.0	0.0	0.2908	BRAF p.L505H (Missense)	1.0	MEL-IPI_Pat128	MEL-IPI_Pat128-Tumor-SM-5X2R6	MEL-IPI_Pat128-Normal-SM-5VWHQ
Investigate Actionability	Clinical trial			Somatic Variant	ATM	Splice Site		0.8036	56.0	0.0	0.0		Investigate Actionability	BAY 1895344	ATR inhibition	Targeted therapy	The ATR inhibitor BAY 1895344 is tolerated at biologically active doses with anti-tumor activity against cancers with certain DDR defects, including ATM protein loss, in patients with advanced metastatic solid tumors resistant or refractory to standard treatment, with and without DDR defects.	De Bono JS, Tan DSP, Caldwell R, et al. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. JCO. 2019; 37(15_suppl):3007-3007.	https://10.1200/JCO.2019.37.15_suppl.3007													0	1.0	1.0	0.0	ATM  (Splice Site)		MEL-IPI_Pat128	MEL-IPI_Pat128-Tumor-SM-5X2R6	MEL-IPI_Pat128-Normal-SM-5VWHQ
Investigate Actionability	Preclinical	Clinical evidence		Somatic Variant	FLT3	Missense	p.P986L	0.7368	76.0	1.6e-05	0.0		Investigate Actionability	Sunitinib	targets FLT3	Targeted therapy	Sunitinib successfully inhibits cellular proliferation of cells Ba/F3 FLT3 K663Q cells in a dose-dependent manner.	Schittenhelm MM, Yee KW, Tyner JW, et al. FLT3 K663Q is a novel AML-associated oncogenic kinase: Determination of biochemical properties and sensitivity to Sunitinib (SU11248). Leukemia. 2006;20(11):2008-14.	https://doi.org/10.1038/sj.leu.2404374	Investigate Actionability	Quizartinib	targets FLT3	Targeted therapy	A second FTL3 internal tanden duplication mutation (FTL3 p.F691L) was detected in a patient with acute myeloid leukemia at the time of relapse followed Quizartinib (AC220) treatment. Normal karyotype of NPM1 and FLT3-ITD was observed before treatment.	Albers C, Leischner H, Verbeek M, et al. The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib. Leukemia. 2013;27(6):1416-8.	https://doi.org/10.1038/leu.2013.14						0	1.0	0.0	0.0	FLT3 p.P986L (Missense)	1.0	MEL-IPI_Pat128	MEL-IPI_Pat128-Tumor-SM-5X2R6	MEL-IPI_Pat128-Normal-SM-5VWHQ
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat128		
Biologically Relevant				Rearrangement	CTNNB1	Fusion	CTNNB1--SNORA49			0.0	0.0																					0				CTNNB1--SNORA49 Fusion		MEL-IPI_Pat128		
Biologically Relevant				Rearrangement	CDK4	Fusion	CDK4--PRKAR1A			0.0	0.0																					0				CDK4--PRKAR1A Fusion		MEL-IPI_Pat128		
Biologically Relevant				Rearrangement	CTNNB1	Fusion	SNRPD1--CTNNB1			0.0	0.0																					0				SNRPD1--CTNNB1 Fusion		MEL-IPI_Pat128		
Biologically Relevant				Rearrangement	MSH6	Fusion	RLF--MSH6			0.0	0.0																					0				RLF--MSH6 Fusion		MEL-IPI_Pat128		
Biologically Relevant				Copy Number	MAP2K1	Amplification				0.0	0.0																					0				MAP2K1 Amplification		MEL-IPI_Pat128	MEL-IPI_Pat128-Tumor-SM-5X2R6	
Biologically Relevant				Copy Number	NTRK3	Amplification				0.0	0.0																					0				NTRK3 Amplification		MEL-IPI_Pat128	MEL-IPI_Pat128-Tumor-SM-5X2R6	
Biologically Relevant				Copy Number	BLM	Amplification				0.0	0.0																					0				BLM Amplification		MEL-IPI_Pat128	MEL-IPI_Pat128-Tumor-SM-5X2R6	
Biologically Relevant				Copy Number	IDH2	Amplification				0.0	0.0																					0				IDH2 Amplification		MEL-IPI_Pat128	MEL-IPI_Pat128-Tumor-SM-5X2R6	
Biologically Relevant				Microsatellite Stability	Supporting variants		RLF--MSH6 Fusion, PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: RLF--MSH6 Fusion, PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat128		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.555																									0				COSMIC Signature (version 2) 7 (56%)		MEL-IPI_Pat128		
